A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
Latest Information Update: 21 May 2024
At a glance
- Drugs Clazakizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 16 May 2024 Status changed from active, no longer recruiting to completed.
- 12 Mar 2024 Planned End Date changed from 31 Dec 2024 to 30 Jun 2024.
- 12 Mar 2024 Planned primary completion date changed from 31 Dec 2024 to 30 Jun 2024.